Why hasn't NEU done a ROW deal by now?
We know that Acadia has been knocked back at least once, presumably because it was below expectations. We also know that, apart from the low upfront payment for NA rights, that the final NA deal was substantially back-ended in NEU's favor.
A ROW deal is almost certainly going to include a clause that allows the prospective partner to exit if Trofinetide is not approved by the FDA.
Given that is the case, it is therefore understandable that NEU is in no hurry to get the ROW deal done.
Approval gives certainty and puts NEU is the strongest possible position.
Therefore, why not wait?
Share Price, page-1323
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.97 |
Change
0.070(0.35%) |
Mkt cap ! $2.552B | |||
| Open | High | Low | Value | Volume |
| $20.22 | $20.44 | $19.85 | $4.194M | 209.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2772 | $19.93 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.99 | 3310 | 1 |
View Market Depth
| Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |